Automate Your Wheel Strategy on ENTX
With Tiblio's Option Bot, you can configure your own wheel strategy including ENTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENTX
- Rev/Share 0.0051
- Book/Share 0.4468
- PB 4.5887
- Debt/Equity 0.0114
- CurrentRatio 13.0733
- ROIC 0.082
- MktCap 93177010.0
- FreeCF/Share -0.1463
- PFCF -14.6856
- PE -17.939
- Debt/Assets 0.0102
- DivYield 0
- ROE -0.4672
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Entera Bio Ltd. (ENTX)
- IPO Date 2018-06-28
- Website https://www.enterabio.com
- Industry Biotechnology
- CEO Ms. Miranda J. Toledano M.B.A.
- Employees 18
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.